Valuation : ALLOVIRPAR

Market Cap 4.92Cr 4.23Cr 3.97Cr 3.64Cr 6.79Cr 465.2Cr 6.84Cr 47Cr 18Cr 237.73Cr 18Cr 18Cr 765.65Cr P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -6.91Cr -5.94Cr -5.58Cr -5.1Cr -9.52Cr -653Cr -9.6Cr -66Cr -26Cr -333.71Cr -26Cr -25Cr -1.07TCr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day+0.90%
Current month-59.43%
Current year-59.43%
3 years 3.9
Extreme 3.905
76.24
5 years 3.9
Extreme 3.905
607.43
10 years 3.9
Extreme 3.905
1,126.08

Financials

2023 2024
Net sales - -
Net income -19Cr -16Cr -15Cr -14Cr -26Cr -1.8TCr -26Cr -181.88Cr -71Cr -919.89Cr -72Cr -70Cr -2.96TCr -5.88Cr -5.06Cr -4.75Cr -4.34Cr -8.1Cr -555.55Cr -8.17Cr -56Cr -22Cr -283.91Cr -22Cr -22Cr -914.36Cr
Net Debt -16Cr -13Cr -13Cr -12Cr -22Cr -1.48TCr -22Cr -149.49Cr -58Cr -756.1Cr -59Cr -57Cr -2.44TCr -12Cr -10Cr -9.55Cr -8.74Cr -16Cr -1.12TCr -16Cr -112.98Cr -44Cr -571.44Cr -44Cr -43Cr -1.84TCr
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change
04/26/04 $3.980 +2.05%
02/26/02 $3.900 -0.51%
01/26/01 $3.920 -2.97%
31/26/31 $4.040 +0.25%
28/26/28 $4.030 -1.71%
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock